ethyl{5-[3-(5-fluoro-1H-benzimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-4-methylpyridin-3-ylmethyl}carbamic acid tert-butyl ester | 837364-63-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: ethyl{5-[3-(5-fluoro-1H-benzimidazol-2-yl)-1-(tetrahydropyran-2-yl)-1H-indazol-5-yl]-4-methylpyridin-3-ylmethyl}carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-ethyl-N-[[5-[3-(6-fluoro-1H-benzimidazol-2-yl)-1-(oxan-2-yl)indazol-5-yl]-4-methylpyridin-3-yl]methyl]carbamate
• CAS: 837364-63-3
• 化学式: C₃₃H₃₇FN₆O₃
• 分子量: 584.694
• InChiKey: JGFYJLODELKXCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  98.2
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
  申请人：Kephart Elizabeth Susan

  公开号：US20060142345A1

  公开（公告）日：2006-06-29

  3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了调节和/或抑制细胞增殖，如蛋白激酶活性的3,5-双取代吲唑化合物。这些化合物和含有它们的药物组合物能够调节CDK依赖性疾病，以调节和/或抑制不需要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予这些化合物的有效量来治疗癌症以及与不需要的血管生成和/或细胞增殖相关的其他疾病状态，如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
• 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
  申请人：Kephart Elizabeth Susan

  公开号：US20050026960A1

  公开（公告）日：2005-02-03

  3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

  本文描述了3,5-二取代吲唑化合物，其调节和/或抑制细胞增殖，如蛋白激酶的活性。这些化合物和含有它们的药物组合物能够介导CDK依赖性疾病，以调节和/或抑制不必要的细胞增殖。本发明还涉及含有这些化合物的药物组合物的治疗或预防用途，以及通过给予有效剂量的这些化合物的方法来治疗癌症以及与不必要的血管生成和/或细胞增殖相关的其他疾病状态，例如糖尿病视网膜病变、新生血管性青光眼、类风湿性关节炎和银屑病。
• US7008953B2
  申请人：——

  公开号：US7008953B2

  公开（公告）日：2006-03-07